May 9th 2021
This is the third and final part of our series on National Comprehensive Cancer Network/Pfizer efforts to investigate issues of importance to biosimilar stakeholders.
May 7th 2021
By Tony Hagen
Advances in analytical testing have improved confidence in biosimilars, according to a Medicines for Europe panel.
May 5th 2021
The anatomy of an interchangeability switching study.
May 4th 2021
By Skylar Jeremias
Biosimilar companies partnered with other companies and saw earnings increases, while reference product corporations faced sales erosion from biosimilar competition.
May 3rd 2021
Representative Carolyn B. Maloney, D-New York, questions the use of pharmaceutical profits to defend against biosimilar competition.
May 1st 2021
Biocon tests the waters with itolizumab in pandemic-ravaged India, and Celltrion announces early success with an agent for the South African variant.
April 30th 2021
There's no end in sight for Enbrel (etanercept) sales erosion, but Amgen's biosimilars are holding their own, the company reported.
April 28th 2021
How much muscle did Congress invest in a pair of bills recently signed by President Biden? The answer may lie in your willingness to believe.
April 27th 2021
By Deana Ferreri, PhD
The savings from pegfilgrastim biosimilars rapidly add up, according to a study simulation that accounted for hospital costs associated with the on-body injector.
April 26th 2021
Investigators tapped health system data to conduct an observational, real-world comparison of bevacizumab (Mvasi) vs the reference product (Avastin).
